Press Releases

Press Releases

Date Title Views
December 6, 2018
SAN FRANCISCO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of William Lis , to Eidos’ Board of
November 14, 2018
SAN FRANCISCO , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present a company overview at two upcoming investor conferences. Piper Jaffray Healthcare Conference The company will give a corporate presentation on Wednesday,
November 10, 2018
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised Serum TTR Concentrations (p
November 6, 2018
SAN FRANCISCO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today reported its financial results for the quarter ended September 30,
October 29, 2018
SAN FRANCISCO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical trial of AG10 in patients with transthyretin amyloidosis cardiomyopathy and
October 26, 2018
SAN FRANCISCO , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ), announced today that the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for the designation of Eidos’ product candidate, AG10, as
October 5, 2018
SAN FRANCISCO , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking
October 3, 2018
SAN FRANCISCO , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), announced today that the U.S.
September 25, 2018
SAN FRANCISCO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 at 3:30 p.m. ET .
September 17, 2018

SAN FRANCISCO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq:EIDX) announced the presentation of results from its Phase 1 clinical trial of AG10 during a poster session at the 22 nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA).

Displaying 1 - 10 of 18